These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32768596)

  • 41. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
    J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
    Schild MH; Guy CD
    Surg Pathol Clin; 2018 Jun; 11(2):267-285. PubMed ID: 29751874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Nonalcoholic Fatty Liver Disease Fibrosis Score Is Related to Epicardial Fat Thickness and Complexity of Coronary Artery Disease.
    Turan Y
    Angiology; 2020 Jan; 71(1):77-82. PubMed ID: 31018673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
    Bedossa P; Patel K
    Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Non-invasive biomarkers of fibrosis for the screening of patients with metabolic steatopathy (NAFLD): a significant role for all biologists].
    Peoc'h K; Castera L
    Ann Biol Clin (Paris); 2019 Apr; 77(2):125-127. PubMed ID: 30998192
    [No Abstract]   [Full Text] [Related]  

  • 47. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
    Netanel C; Goitein D; Rubin M; Kleinbaum Y; Katsherginsky S; Hermon H; Tsaraf K; Tachlytski I; Herman A; Safran M; Ben-Ari Z
    Am J Surg; 2021 Jul; 222(1):214-219. PubMed ID: 33309037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults.
    Guo W; Lu J; Qin P; Li X; Zhu W; Wu J; Xu N; Zhang Q
    Lipids Health Dis; 2020 Oct; 19(1):218. PubMed ID: 33028338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
    Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
    World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.
    Jamali R; Razavizade M; Arj A; Aarabi MH
    World J Gastroenterol; 2016 Jun; 22(21):5096-103. PubMed ID: 27275102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
    Castera L
    Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).
    Lopez-Mendez I; Aquino-Matus J; Gall SM; Prieto-Nava JD; Juarez-Hernandez E; Uribe M; Castro-Narro G
    Ann Hepatol; 2021; 20():100271. PubMed ID: 33099028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.
    Kessoku T; Ogawa Y; Yoneda M; Imajo K; Sumida Y; Eguchi Y; Fujii H; Hyogo H; Ono M; Suzuki Y; Kawaguchi T; Chayama K; Tanaka S; Fujimoto K; Anzai K; Saibara T; Sata M; Itoh Y; Nakajima A; Okanoue T;
    World J Gastroenterol; 2014 Aug; 20(29):10108-14. PubMed ID: 25110437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
    Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
    Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk.
    Jiang L; Yang M; Li X; Wang Y; Zhou G; Zhao J
    J Clin Endocrinol Metab; 2018 Nov; 103(11):3974-3985. PubMed ID: 30053055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.
    Konishi K; Miyake T; Furukawa S; Senba H; Kanzaki S; Nakaguchi H; Yukimoto A; Nakamura Y; Watanabe T; Koizumi Y; Yoshida O; Tokumoto Y; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
    Atherosclerosis; 2020 Apr; 299():32-37. PubMed ID: 32203743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
    Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
    J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.